I am a physician scientist focused on the treatment and study of primary liver cancers. I attend in the Gastrointestinal Oncology Group and run a research group in the Quantitive Biosciences Institute. My laboratory applies proteomic methods to identify novel targets and improve the application of existing therapeutics for liver cancers including hepatocellular carcinoma, cholangiocarcinoma and fibrolamellar liver cancer. We have three major areas of investigation:
1. Mapping oncogenic kinase signaling and its response to targeted therapeutics to define biomarkers and combination treatments for clinically relevant agents
2. Characterizing the impact of hepatitis viruses on liver cancer and its response to treatment
3. Developing small molecule strategies to target Hippo pathway dysregulation